In a regulatory filing, Catalyst Pharmaceuticals (CPRX) president and CEO Richard Daly disclosed the purchase of 70,000 common shares of the company on May 30 at a price of $24.86 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharma Appoints New Chief Medical Officer
- Catalyst Pharmaceuticals appoints William Andrews as CMO
- Catalyst Pharma Holds 2025 Annual Stockholders Meeting
- Catalyst Pharma’s Strong Commercial Performance and Promising Revenue Guidance Justify Buy Rating
- Catalyst Pharma’s Strong Growth Prospects and Strategic Initiatives Drive Buy Rating
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue